Navigation Links
Duke to test bird flu vaccine dosing

A clinical trial to test different strengths of a vaccine designed to fight avian influenza will begin this month at Duke University Medical Center.

The Duke study is part of a multicenter trial that will test a modified form of an investigational bird flu vaccine to determine whether the vaccine still triggers a strong immune response at lower doses.

The seven-month trial is sponsored by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. Also participating in the study are the University of Maryland, the University of Rochester and Baylor College of Medicine.

"We hope that by adding a compound called an adjuvant to the vaccine, we can create a stronger immune response to smaller doses of the vaccine," said Emmanuel Walter, M.D., associate director of the Duke Clinical Research Institute's Primary Care Research Consortium and leader of the Duke study. "If the smaller dose stimulates immunity against the virus, then more people could be immunized with existing supplies if a pandemic occurs," he said.

The study will use an inactivated flu virus vaccine based on a strain taken from a Vietnamese patient in 2004. "There is no live flu virus in the vaccine, and there is no risk of volunteers contracting bird flu or spreading it to others," Walter said.

The vaccine is designed to protect against the H5N1 strain of bird flu that has infected poultry in Asia, Europe and Africa and killed 101 humans. Initial trials in healthy adults showed the vaccine was safe and produced an immune response but required high doses and at least two injections to initiate a strong response, Walter said.

Trial participants will receive varying strengths of the H5N1 vaccine, either with or without an aluminum hydroxide adjuvant. An adjuvant works by increasing the body's immune response to a vaccine, Walter said. Aluminum hydroxide is commonly used in pediatric and adult vaccines, including those for wh ooping cough, hepatitis A and hepatitis B.

As with current flu vaccines given yearly in the U.S., the H5N1 vaccine causes the body's immune system to make antibodies to fight infection. In previous studies with this vaccine, two doses were necessary to stimulate antibodies. The doses needed to trigger antibodies were also much higher than necessary for other types of flu, Walter said.


'"/>

Source:Duke University Medical Center


Related biology news :

1. Research advances quest for HIV-1 vaccine
2. A much-needed shot in the arm for HIV vaccine development
3. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
4. Gene vaccine for Alzheimers disease shows promising results
5. Influenza vaccine uses insect cells to speed development
6. Norovirus, AIDS vaccine and Hepatitis Virus
7. HIV vaccine trial breaks ground for future research
8. Live vaccines more effective against horse herpes virus
9. NIAID begins clinical trial of West Nile virus vaccine
10. Designing vaccines by computer
11. Wake Forest scientists find new combination vaccine effective against plague
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
(Date:4/13/2017)... 13, 2017 UBM,s Advanced Design and Manufacturing ... feature emerging and evolving technology through its 3D Printing ... run alongside the expo portion of the event and ... demonstrations focused on trending topics within 3D printing and ... manufacturing event will take place June 13-15, 2017 at the ...
(Date:4/11/2017)... 2017 No two people are believed ... New York University Tandon School of Engineering and ... that partial similarities between prints are common enough ... phones and other electronic devices can be more ... lies in the fact that fingerprint-based authentication systems ...
Breaking Biology News(10 mins):
(Date:7/20/2017)... and PLYMOUTH, Minn., July 20, 2017   KCNQ2 ... personalized genetic evaluations company, today announced that they ... investigating a genetic mutation implicated in KCNQ2 epileptic ... partnership for a second case involving an additional ... KCNQ2 Cure Alliance and Pairnomix entered into a ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... make clinical trial sites and study participants truly unified. TrialKit, a native mobile ... 21 CFR Part 11) research studies entirely on mobile devices. With TrialKit, clinical ...
(Date:7/18/2017)... ... ... Sourcing custom glass or quartz parts can be a daunting task. Finding ... your job can take many hours of emails, phone calls and on-line research. Wilmad-LabGlass’ ... the company’s capabilities and core custom categories, and enables you to start the quoting ...
(Date:7/18/2017)... ... July 18, 2017 , ... G-CON today announced that ... Office for its Patent Applications 14/858,857 and 13/669,785 both entitled Modular, Self-Contained, Mobile ... further expand the protection of G-CON’s R&D investments and validate the G-CON platform ...
Breaking Biology Technology: